Svendsen succeeds Peder M. Andersen, who has led the company since 2012. Svendsen previously held the position of Executive Vice President.
He joined the company in 2015, prior to which he held positions of increasing seniority in the Danish pharmaceutical company, Novo Nordisk. His last role there was Global Medical Director.
Previously, Svendsen worked in biotech venture capital and has a clinical background in internal medicine. He graduated as a Medical Doctor from University of Copenhagen in 2003, and additionally completed a Ph.D. in sarcoidosis pathobiology in 2009.
“Claus' dedication and strong work ethic make him ideally suited to lead the Company as we pursue our opportunities in connection with the Settlement and License Agreement with Biogen,” said Florian Schönharting, Chairman of the Board of Directors.
“We thank Peder for his years of hard work, commitment and significant contributions to the company.”
“I am excited to assume leadership of the Company and pursue our important objectives ahead in connection with the Settlement and License Agreement with Biogen,” said Svendsen.
The company has also announced plans to wind up its remaining research and development efforts and pursue an organisational realignment to reduce personnel and operating expenses by mid-year 2017.
